BIMI International Medical (FRA:63N) 3-Year EBITDA Growth Rate : 10.40% (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is BIMI International Medical 3-Year EBITDA Growth Rate?

BIMI International Medical's EBITDA per Share for the three months ended in Sep. 2023 was €-0.45.

During the past 3 years, the average EBITDA Per Share Growth Rate was 10.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -66.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of BIMI International Medical was 26.80% per year. The lowest was -247.60% per year. And the median was -32.10% per year.

Competitive Comparison of BIMI International Medical's 3-Year EBITDA Growth Rate

For the Pharmaceutical Retailers subindustry, BIMI International Medical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BIMI International Medical's 3-Year EBITDA Growth Rate Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, BIMI International Medical's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where BIMI International Medical's 3-Year EBITDA Growth Rate falls into.

BIMI International Medical 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

BIMI International Medical (FRA:63N) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

BIMI International Medical 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of BIMI International Medical's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

BIMI International Medical (FRA:63N) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » BIMI International Medical Inc (FRA:63N) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

BIMI:USA

Address

Chongqing Corporation Avenue, 9th Floor, Building 2, Yuzhong District, Chongqing, CHN, 400010

Website

https://www.usbimi.com

BIMI International Medical Inc is a healthcare product and provider, offering a broad range of healthcare products and related services and operates private hospitals in China. The company is engaged in four business segments, Pharmaceuticals wholesale, Medical devices wholesale, Medical services, and Pharmacy retail. It generates maximum revenue from the pharmaceuticals wholesale segment. It mainly sources its products from large state-owned pharmaceutical manufacturers and wholesalers and mid-sized or small private pharmaceutical manufacturers and wholesalers. The Company's revenues were generated in the PRC.

BIMI International Medical (FRA:63N) Headlines

No Headlines